Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PMVP
stocks logo

PMVP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.405
-10%
--
--
-0.333
-1.96%
--
--
-0.360
-12.2%
Estimates Revision
Stock Price
Go Down
down Image
-12.33%
In Past 3 Month
Wall Street analysts forecast PMVP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMVP is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast PMVP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMVP is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.280
sliders
Low
5.00
Averages
5.00
High
5.00
Current: 1.280
sliders
Low
5.00
Averages
5.00
High
5.00
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$5
2025-03-20
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$5
2025-03-20
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for PMV Pharmaceuticals Inc (PMVP.O) is -0.88, compared to its 5-year average forward P/E of -7.86. For a more detailed relative valuation and DCF analysis to assess PMV Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.86
Current PE
-0.88
Overvalued PE
1.57
Undervalued PE
-17.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.07
Undervalued EV/EBITDA
-14.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2450.33% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PMVP News & Events

Events Timeline

(ET)
2025-11-12
08:05:12
PMV Pharmaceuticals Announces Q3 Earnings Per Share of 40 Cents, Matching Expectations
select
2025-10-24 (ET)
2025-10-24
11:46:20
PMV Pharmaceuticals reveals new interim data on rezatapopt monotherapy
select
2025-09-10 (ET)
2025-09-10
07:03:00
PMV Pharmaceuticals Reveals Interim Results from Phase 2 Segment of PYNNACLE
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-24Newsfilter
PMV Pharmaceuticals Reveals New Interim Data on Rezatapopt Monotherapy from Ongoing PYNNACLE Phase 2 Trial for Various Solid Tumors with TP53 Y220C Mutation

  • Clinical Trial Results: Updated data from the Phase 2 PYNNACLE trial presented at the 2025 AACR-NCI-EORTC Conference showed a 34% overall response rate (ORR) across eight tumor types, with a notable 46% ORR in the ovarian cancer cohort.

  • Rezatapopt Overview: Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate the p53 protein in tumors with the TP53 Y220C mutation, with plans for a New Drug Application submission for platinum-resistant ovarian cancer in Q1 2027.

  • Safety Profile: The treatment was generally well-tolerated, with most adverse events being Grade 1-2, and a low discontinuation rate due to treatment-related adverse events (3.6%).

  • Future Directions: PMV Pharma aims to continue generating data to support regulatory strategies and enhance treatment options for patients with advanced solid tumors harboring the TP53 Y220C mutation.

[object Object]
Preview
9.0
09-11Benzinga
PMV Pharmaceuticals' Small-Cap Cancer Drug Demonstrates Verified Efficacy Across 8 Tumor Types

  • Clinical Trial Results: PMV Pharmaceuticals released interim data from the Phase 2 PYNNACLE trial, showing a 33% overall response rate for rezatapopt in patients with advanced solid tumors harboring the TP53 Y220C mutation, with notable efficacy in ovarian (43% ORR) and endometrial (60% ORR) cancers.

  • Safety and Regulatory Plans: The treatment was generally well-tolerated, with most adverse events being mild. PMV Pharma plans to enroll additional patients for a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer by early 2027, following FDA feedback.

[object Object]
Preview
9.0
09-10NASDAQ.COM
PMV Pharma Announces Encouraging Interim Results from Phase 2 PYNNACLE Trial

  • Positive Interim Data: PMV Pharmaceuticals announced positive interim results from the Phase 2 portion of the PYNNACLE study, showing a 33% overall response rate in patients with advanced solid tumors, particularly those with TP53 Y220C mutations and KRAS wild-type.

  • Ovarian Cancer Focus: The study reported a 43% response rate in the ovarian cancer cohort, with a median duration of response of 7.6 months, and the company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer by Q1 2027.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is PMV Pharmaceuticals Inc (PMVP) stock price today?

The current price of PMVP is 1.28 USD — it has decreased -0.78 % in the last trading day.

arrow icon

What is PMV Pharmaceuticals Inc (PMVP)'s business?

PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.

arrow icon

What is the price predicton of PMVP Stock?

Wall Street analysts forecast PMVP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMVP is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is PMV Pharmaceuticals Inc (PMVP)'s revenue for the last quarter?

PMV Pharmaceuticals Inc revenue for the last quarter amounts to -22.52M USD, increased 2.90 % YoY.

arrow icon

What is PMV Pharmaceuticals Inc (PMVP)'s earnings per share (EPS) for the last quarter?

PMV Pharmaceuticals Inc. EPS for the last quarter amounts to -19820000.00 USD, increased 17.70 % YoY.

arrow icon

What changes have occurred in the market's expectations for PMV Pharmaceuticals Inc (PMVP)'s fundamentals?

The market is revising No Change the revenue expectations for PMVP for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -12.33%.
arrow icon

How many employees does PMV Pharmaceuticals Inc (PMVP). have?

PMV Pharmaceuticals Inc (PMVP) has 63 emplpoyees as of December 05 2025.

arrow icon

What is PMV Pharmaceuticals Inc (PMVP) market cap?

Today PMVP has the market capitalization of 68.11M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free